We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

71 hedge funds and large institutions have $86.1M invested in Endocyte, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

626% more capital invested

Capital invested by funds: $11.9M → $86.1M (+$74.2M)

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

13% more funds holding

Funds holding: 63 → 71 (+8)

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

59% less call options, than puts

Call options by funds: $737K | Put options by funds: $1.79M

Holders
71
Holders Change
+8
Holders Change %
+12.7%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
16
Reduced
15
Closed
17
Calls
$737K
Puts
$1.79M
Net Calls
-$1.06M
Net Calls Change
-$622K

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$16.4M
2
RCM
RA Capital Management
Massachusetts
+$16M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$7.91M
4
PA
Perceptive Advisors
New York
+$6.92M
5
BBA
Baker Bros. Advisors
New York
+$5.18M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.63M
2
Millennium Management
Millennium Management
New York
-$609K
3
SIM
Spark Investment Management
New York
-$569K
4
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$383K
5
PAM
Panagora Asset Management
Massachusetts
-$353K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$289K +$308K +64,601 +2,221%
SIM
27
Spark Investment Management
New York
$244K -$569K -119,500 -68%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$219K +$77.6K +16,283 +46%
CCM
29
Cribstone Capital Management
Maine
$203K – – –
PCM
30
Prelude Capital Management
New York
$183K +$200K +42,058 +7,010%
AGM
31
Alpine Global Management
New York
$144K +$160K +33,675 New
1SB
32
1ST Source Bank
Indiana
$141K – – –
LCM
33
Leisure Capital Management
California
$121K +$2.77K +581 +2%
ProShare Advisors
34
ProShare Advisors
Maryland
$110K +$123K +25,795 New
Axa
35
Axa
France
$101K +$112K +23,500 New
BTS
36
BB&T Securities
Virginia
$88K – – –
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$77K -$138K -28,867 -62%
SG
38
Strid Group
Pennsylvania
$77K +$85.8K +18,000 New
Ameriprise
39
Ameriprise
Minnesota
$75K -$117K -24,500 -58%
State Street
40
State Street
Massachusetts
$72K – – –
VF
41
Virtu Financial
New York
$72K +$80.2K +16,824 New
PA
42
Pinnacle Associates
New York
$70K -$78.3K -16,425 -50%
MIM
43
Monashee Investment Management
Massachusetts
$65K – – –
WAM
44
Weiss Asset Management
Massachusetts
$61K +$68.3K +14,342 New
Group One Trading
45
Group One Trading
Illinois
$58K -$15.9K -3,342 -20%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$55K -$27.3K -5,728 -31%
Charles Schwab
47
Charles Schwab
California
$49K – – –
SBIA
48
Sheaff Brock Investment Advisors
Indiana
$46K +$51K +10,700 New
HH
49
Hilltop Holdings
Texas
$46K +$51.1K +10,720 New
WS
50
Wedbush Securities
California
$45K +$50.5K +10,600 New
1
2
3 4

ECYT Hedge Fund Activity: Q4 2017 in Review

71 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2017, worth a combined $86.1M — up 626% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ECYT positions and 17 closed out — a net gain of 8 holders — while 16 added to existing stakes and 15 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $16.4M. The largest seller was Fidelity Investments, cutting an estimated $1.63M.

  • 71 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2017, up from 63 in Q3 2017.
  • Funds reported $86.1M of Endocyte, Inc. Common Stock stock for Q4 2017, up 626% quarter-over-quarter.
  • 25 funds opened new Endocyte, Inc. Common Stock positions in Q4 2017 and 17 closed out, a net change of +8 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q4 2017 was PFM Health Sciences, an estimated $16.4M added.
  • The largest Endocyte, Inc. Common Stock seller in Q4 2017 was Fidelity Investments, an estimated $1.63M sold.

Based on aggregated 13F filings for Q4 2017.